Top

Published in:

Open Access 01-12-2020 | Letter

Optimizing ceftolozane-tazobactam dosage during continuous renal replacement therapy: some nuances

Authors: Gerardo Aguilar, Rafael Ferriols, Sara Martínez-Castro, Carlos Ezquer, Ernesto Pastor, Jose A. Carbonell, Manuel Alós, David Navarro

Published in: Critical Care | Issue 1/2020

Excerpt

We have read the recent letter by Honore et al. [1] about our findings published in this journal regarding the influence of continuous renal replacement therapy (CRRT) on the pharmacokinetics of ceftolozane-tazobactam (C/T) [2]. In our report, we decided to administer a 3 g/iv dose every 8 h taking into account two previous studies referenced in our paper [2] and another one which showed CRRT to be an independent predictor of clinical failure (OR 4.5, 95% CI 1.18–17.39, p = 0.02) when C/T is administered at 1.5 g every 8 h [3]. …

Honore PM, Mugisha A, Gutierrez LB, Redant S, Kaefer K, Gallerani A, De Bels D. Optimizing ceftolozane-tazobactam dosage during continuous renal replacement therapy: additional insights. Crit Care. 2019;23(1):406.CrossRef

Aguilar G, Ferriols R, Martínez-Castro S, Ezquer C, Pastor E, Carbonell JA, Alós M, Navarro D. Optimizing ceftolozane-tazobactam dosage in critically ill patients during continuous venovenous hemodiafiltration. Crit Care. 2019;23(1):145.CrossRef

Bassetti M, Castaldo N, Cattelan A, Mussini C, Righi E, Tascini C, et al. Ceftolozane/tazobactam for the treatment of serious P. aeruginosa infections: a multicenter nationwide clinical experience. Int J Antimicrob Agents. 2019 Apr;53(4):408–15.CrossRef

Honore PM, Spapen HD. What a clinician should know about a renal replacement membrane? J Transl Intern Med. 2018;6:62–5.CrossRef

Lee YR, Miller PD, Alzghari SK, Blanco DD, Hager JD, Kuntz KS. Continuous infusion versus intermittent bolus of beta-lactams in critically ill patients with respiratory infections: a systematic review and meta-analysis. Eur J Drug Metab Pharmacokinet. 2018;43(2):155–70.CrossRef

Title: Optimizing ceftolozane-tazobactam dosage during continuous renal replacement therapy: some nuances
Authors: Gerardo Aguilar
Rafael Ferriols
Sara Martínez-Castro
Carlos Ezquer
Ernesto Pastor
Jose A. Carbonell
Manuel Alós
David Navarro
Publication date: 01-12-2020
Publisher: BioMed Central
Published in: Critical Care / Issue 1/2020
Electronic ISSN: 1364-8535
DOI: https://doi.org/10.1186/s13054-019-2724-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Optimizing ceftolozane-tazobactam dosage during continuous renal replacement therapy: some nuances

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2020

Gastrointestinal dysfunction in the critically ill: a systematic scoping review and research agenda proposed by the Section of Metabolism, Endocrinology and Nutrition of the European Society of Intensive Care Medicine

The importance of a “socially responsible” approach during COVID-19: the invisible heroes of science in Italy

The effect of cisatracurium infusion on the energy expenditure of critically ill patients: an observational cohort study

Effect of therapeutic plasma exchange on endothelial activation and coagulation-related parameters in septic shock

Surgery for spontaneous intracerebral hemorrhage

Mechanical ventilation and neurocritical patients: is there a role for anti-neuroinflammatory therapies?